Autolus Therapeutics plc
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- AUTLAutolus Limited0Calm
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Invite-only sign-upPhase 2500 patientsMain results: Jul 2043 - AUTLAutolus Limited0Calm
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Running, no new patientsPhase 1/2153 patientsMain results: Jun 30, 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
1 sale (1 not pre-planned) · 0 purchases
- Piccina CintiaU.S. CCO & Country Gen Manager · Sep 2, 2026Sold 6,713 sharesabout $16 thousand · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Permission to sell new sharesPermission to sell new shares (S-3)Sep 14, 2026
- Quarterly reportQuarterly report (10-Q)Aug 11, 2026
- Shared quarterly results; Shared information with investorsNews report (8-K)Aug 11, 2026
- Shared information with investors; Other newsNews report (8-K)Aug 3, 2026
- Signed a major agreementNews report (8-K)Aug 3, 2026